Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer

Bradley J Monk¹, Robert L Coleman¹, David M O'Malley¹+3

• ¹Bradley J. Monk, MD, Florida Cancer Specialists & Research Institute, West Palm Beach, FL; Robert L. Coleman, MD, Texas Oncology, The Woodlands, TX; David M. O'Malley, MD, The Ohio State University, James Cancer Center, Columbus, OH; Kathleen N. Moore, MD, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Antonio González-Martín, MD, Cancer Center Clínica Universidad de Navarra, Madrid, Spain; and Thomas J. Herzog, MD, University of Cincinnati, University of Cincinnati Cancer Center, Cincinnati, OH.